1
|
Al Zarkali O, Marker A, Kaur L, VanDerWall A. A Unique Case of Late Presentation Giant Lower Extremity Malignant Melanoma. Cureus 2024; 16:e55414. [PMID: 38567210 PMCID: PMC10985282 DOI: 10.7759/cureus.55414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/02/2024] [Indexed: 04/04/2024] Open
Abstract
This case describes a unique presentation of a rare malignancy: giant melanoma. Due to the accessibility of healthcare in the United States, it is unusual for melanomas to grow to massive sizes without clinical intervention. In fact, an in-depth literature review elicited only a handful of similar cases. Giant malignant melanomas are typically defined by a cutoff size of no less than 10 cm in diameter. They often present with distant metastases and are highly invasive. Due to limited yet highly variable presentations, there is no standardized approach to treating this class of melanomas. We present a case with unique features not previously documented in similar cases that was ultimately treated with a novel approach.
Collapse
Affiliation(s)
- Omar Al Zarkali
- Internal Medicine, HCA Florida Blake Hospital, Bradenton, USA
| | - Amanda Marker
- Internal Medicine, HCA Florida Blake Hospital, Bradenton, USA
| | - Lakhvir Kaur
- Internal Medicine, HCA Florida Blake Hospital, Bradenton, USA
| | - Ana VanDerWall
- Medical Oncology, HCA Florida Blake Hospital, Bradenton, USA
| |
Collapse
|
2
|
Putnam H, Turnbull A, Bangura J, Kitsanta P, Grobusch MP, Dubbink JH. Case Report: Acral Melanoma with Giant Local Recurrence in Rural Sierra Leone. Am J Trop Med Hyg 2022; 107:912-915. [PMID: 35995134 PMCID: PMC9651533 DOI: 10.4269/ajtmh.21-1273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 06/13/2022] [Indexed: 11/07/2022] Open
Abstract
Malignant melanoma is rare in West Africa. Few cases of giant melanoma have been reported globally. We present a case of acral melanoma with giant local recurrence on the foot of a black-skinned woman from rural Sierra Leone, managed with below-knee amputation. Atypical, late presentation, poor access to diagnostics, and underreporting may contribute to underappreciation of melanoma as a healthcare problem in West Africa. This case highlights the need for improved cancer and skin health surveillance structures in West Africa-most importantly, increasing access to histopathology.
Collapse
Affiliation(s)
- Harry Putnam
- Masanga Hospital, Masanga, Tonkolili District, Sierra Leone
- Masanga Medical Research Unit (MMRU), Masanga, Tonkolili District, Sierra Leone
| | - Alexandra Turnbull
- Masanga Hospital, Masanga, Tonkolili District, Sierra Leone
- Masanga Medical Research Unit (MMRU), Masanga, Tonkolili District, Sierra Leone
| | - James Bangura
- Masanga Hospital, Masanga, Tonkolili District, Sierra Leone
- Masanga Medical Research Unit (MMRU), Masanga, Tonkolili District, Sierra Leone
| | - Panagiota Kitsanta
- Histopathology Department, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
| | - Martin P. Grobusch
- Masanga Medical Research Unit (MMRU), Masanga, Tonkolili District, Sierra Leone
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, The Netherlands
| | - Jan H. Dubbink
- Masanga Hospital, Masanga, Tonkolili District, Sierra Leone
- Masanga Medical Research Unit (MMRU), Masanga, Tonkolili District, Sierra Leone
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
3
|
Mawhinney JA, Yvon A, Masood S. Case Report and Literature Review of Giant Cutaneous Malignant Melanoma: What's Keeping Patients Away? EPLASTY 2022; 22:e45. [PMID: 36212603 PMCID: PMC9516761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Background. Giant cutaneous malignant melanoma (MM) is a term that has previously been used to define lesions that are at least 10 cm in diameter or 48 mm in thickness. Such tumours are rare. There is no substantial body of evidence considering why patients may delay presentation with MM until they reach this size. This case report presents one of the largest cases of giant cutaneous MM to date and the first in the literature to show excellent response to adjuvant immunotherapy. The patient was treated successfully and remains alive and well 12 months following initial surgery. A review of the literature discussing giant MM identified a significant need for education on the importance of seeking medical attention in order to prevent advanced disease, especially for vulnerable individuals.
Collapse
Affiliation(s)
- Jamie A Mawhinney
- Department of Plastic Surgery, Salisbury District Hospital, Salisbury, UK
| | - Adrien Yvon
- Department of Plastic Surgery, Salisbury District Hospital, Salisbury, UK
| | - Shahid Masood
- Department of Plastic Surgery, Salisbury District Hospital, Salisbury, UK
| |
Collapse
|
4
|
Faderani R, Ali SR, Nijran A, Dobbs TD, Karoo R. Diagnosing and managing a giant primary cutaneous malignant melanoma of the lower limb. J Surg Case Rep 2022; 2022:rjac409. [PMID: 36148142 PMCID: PMC9487200 DOI: 10.1093/jscr/rjac409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Accepted: 08/23/2022] [Indexed: 11/15/2022] Open
Abstract
We present a woman who was referred to our plastic surgery unit with a suspected squamous cell carcinoma following a 3-year history of an enlarging mass on her thigh. Surprisingly, histopathological assessment confirmed the diagnosis of nodular malignant melanoma measuring 77×77×54 mm with a Breslow thickness of 52 mm, making it the largest recorded lower limb primary cutaneous malignant melanoma in the UK.
Collapse
Affiliation(s)
- Ryan Faderani
- Faculty of Medicine, University College London , UK
- Welsh Centre for Burns and Plastic Surgery Morriston Hospital , Swansea , UK
| | - Stephen R Ali
- Welsh Centre for Burns and Plastic Surgery Morriston Hospital , Swansea , UK
- Reconstructive Surgery and Regenerative Medicine Research Group , Institute of Life Sciences, , Swansea , UK
- Swansea University Medical School , Institute of Life Sciences, , Swansea , UK
| | - Amit Nijran
- Welsh Centre for Burns and Plastic Surgery Morriston Hospital , Swansea , UK
| | - Thomas D Dobbs
- Welsh Centre for Burns and Plastic Surgery Morriston Hospital , Swansea , UK
- Reconstructive Surgery and Regenerative Medicine Research Group , Institute of Life Sciences, , Swansea , UK
- Swansea University Medical School , Institute of Life Sciences, , Swansea , UK
| | - Richard Karoo
- Welsh Centre for Burns and Plastic Surgery Morriston Hospital , Swansea , UK
| |
Collapse
|
5
|
Rastrelli M, Di Prata C, Del Fiore P, Sbaraglia M, Vindigni V, Bassetto F. Giant inguinal melanoma treated with complex oncological and reconstructive surgery: A case report. Ann Med Surg (Lond) 2022; 80:104320. [PMID: 36045766 PMCID: PMC9422357 DOI: 10.1016/j.amsu.2022.104320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 07/28/2022] [Accepted: 07/31/2022] [Indexed: 11/19/2022] Open
Abstract
A 53-year-old woman came to our attention with a giant inguinal mass that was growing in the last 5 months, so she underwent a total body CT-scan that showed a 25 × 16 × 21cm mass of the right inguinal region which was compressing the femoral vessels and infiltrated the omolateral rectum muscle, pulmonary embolism and thrombosis of the right femoral vein. We performed a tru-cut biopsy that was consistent with an undifferentiated round-cell sarcoma. So, we performed a wide excision of the mass and a reconstruction with a pedunculated muscular flap of the tensor muscle of the fasciae late, a graft of omologous fasciae late and a graft of the great saphena vein onto the superficial femoral artery. The histological examination of the specimen demonstrated instead an “atypical amelanotic sarcomatoid malignant melanoma” with rabdoid aspects. The patient underwent a radicalization surgery and reconstruction with microsurgical great dorsal and anterior serratus flap. To our knowledge, this is the biggest inguinal melanoma treated with surgical excision described so far. Giant primary melanoma is generally accepted as greater than 10 cm, and almost associated with extensive metastatic disease. It is important the patients don't present with such a clinical challenge, the surgery could impact the quality of life. Patients with growing mass must be referred quickly to a diagnosis to obtain a less extent of surgical intervention.
Collapse
|
6
|
Galmarini CM. Lessons from Hippocrates: Time to Change the Cancer Paradigm. Int J Chronic Dis 2020; 2020:4715426. [PMID: 32566644 PMCID: PMC7298279 DOI: 10.1155/2020/4715426] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 05/19/2020] [Indexed: 01/02/2023] Open
Abstract
The ultimate goal of all medical activity is to restore patients to a state of complete physical, mental, and social wellbeing. In cancer, it is assumed that this can only be obtained through the complete eradication of the tumor burden. So far, this strategy has led to a substantial improvement in cancer survival rates. Despite this, more than 9 million people die from cancer every year. Therefore, we need to accept that our current cancer treatment paradigm is obsolete and must be changed. The new paradigm should reflect that cancer is a systemic disease, which affects an individual patient living in a particular social reality, rather than an invading organism or a mere cluster of mutated cells that need to be eradicated. This Hippocratic holistic view will ultimately lead to an improvement in health and wellbeing in cancer patients. They deserve nothing less.
Collapse
Affiliation(s)
- Carlos M. Galmarini
- Topazium Artificial Intelligence, Paseo de la Castellana 40, 28046 Madrid, Spain
| |
Collapse
|
7
|
Retsky M, Demicheli R, Hrushesky W, James T, Rogers R, Baum M, Vaidya JS, Erhabor O, Forget P. Breast cancer and the black swan. Ecancermedicalscience 2020; 14:1050. [PMID: 32565903 PMCID: PMC7289621 DOI: 10.3332/ecancer.2020.1050] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Indexed: 12/13/2022] Open
Abstract
Most current research in cancer is attempting to find ways of preventing patients from dying after metastatic relapse. Driven by data and analysis, this project is an approach to solve the problem upstream, i.e., to prevent relapse. This project started with the unexpected observation of bimodal relapse patterns in breast and a number of other cancers. This was not explainable with the current cancer paradigm that has guided cancer therapy and early detection for many years. After much analysis using computer simulation and input from a number of medical specialties, we eventually came to the conclusion that the surgery to remove the primary tumour produced systemic inflammation for a week after surgery. This systemic inflammation apparently caused exits of cancer cells and micrometastases from dormant states and resulted in relapses in the first 3 years post-surgery. It was determined in a retrospective study that the common inexpensive perioperative non-steroidal anti-inflammatory drug (NSAID) ketorolac could curtail the early relapse events after breast cancer surgery. A second retrospective study strongly confirmed this but an apparently underpowered prospective study showed no advantage. We are analysing these data and are now proposing to test the perioperative NSAID at Beth Israel Deaconess Medical Centre with triple-negative breast cancer (TNBC) patients, the category that could respond best to the perioperative NSAID. If this works as well as we expect, we would then transfer this technology to low- and/or middle-incomes countries (LMICs), starting with Nigeria where early onset type of TNBC is common. There is an unmet need in LMICs, especially in countries like Nigeria (190 million population), for a means to prevent surgery induced relapse that we are attempting to resolve. This work aims, thus, to describe eventual mechanisms, and ways to test a solution addressing an unmet need. But first, we consider the context, including within an historical perspective, important to explain how and why a Kuhnian paradigm shift may be considered.
Collapse
Affiliation(s)
- Michael Retsky
- Harvard T.H. Chan School of Public Health Boston, MA 02115-6021, USA
| | - Romano Demicheli
- University of Milan, Faculty of Medicine and Surgery, Milan 20133, Italy
| | | | - Ted James
- Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215-5400, USA
| | - Rick Rogers
- Harvard T.H. Chan School of Public Health Boston, MA 02115-6021, USA
| | - Michael Baum
- Emeritus Prof, University College London, London N19 5LW, UK
| | | | | | | |
Collapse
|
8
|
Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D. Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. Cancer Res 2018; 78:5349-5362. [PMID: 30026332 DOI: 10.1158/0008-5472.can-18-0644] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 06/12/2018] [Accepted: 07/13/2018] [Indexed: 02/03/2023]
Abstract
Systemic metastasis is the major cause of death from melanoma, the most lethal form of skin cancer. Although most patients with melanoma exhibit a substantial gap between onset of primary and metastatic tumors, signaling mechanisms implicated in the period of metastatic latency remain unclear. We hypothesized that melanoma circulating tumor cells (CTC) home to and reside in the bone marrow during the asymptomatic phase of disease progression. Using a strategy to deplete normal cell lineages (Lin-), we isolated CTC-enriched cell populations from the blood of patients with metastatic melanoma, verified by the presence of putative CTCs characterized by melanoma-specific biomarkers and upregulated gene transcripts involved in cell survival and prodevelopment functions. Implantation of Lin- population in NSG mice (CTC-derived xenografts, i.e., CDX), and subsequent transcriptomic analysis of ex vivo bone marrow-resident tumor cells (BMRTC) versus CTC identified protein ubiquitination as a significant regulatory pathway of BMRTC signaling. Selective inhibition of USP7, a key deubiquinating enzyme, arrested BMRTCs in bone marrow locales and decreased systemic micrometastasis. This study provides first-time evidence that the asymptomatic progression of metastatic melanoma can be recapitulated in vivo using patient-isolated CTCs. Furthermore, these results suggest that USP7 inhibitors warrant further investigation as a strategy to prevent progression to overt clinical metastasis.Significance: These findings provide insights into mechanism of melanoma recurrence and propose a novel approach to inhibit systematic metastatic disease by targeting bone marrow-resident tumor cells through pharmacological inhibition of USP7.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/18/5349/F1.large.jpg Cancer Res; 78(18); 5349-62. ©2018 AACR.
Collapse
Affiliation(s)
- Monika Vishnoi
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas
| | - Debasish Boral
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas
| | - Haowen Liu
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas
| | - Marc L Sprouse
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas
| | - Wei Yin
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas
| | | | - Michael T Tetzlaff
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Michael A Davies
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Isabella C Glitza Oliva
- Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Dario Marchetti
- Biomarker Research Program Center, Houston Methodist Research Institute, Houston, Texas.
| |
Collapse
|
9
|
Yu C, Mitchell JK. Non-randomness of the anatomical distribution of tumors. CANCER CONVERGENCE 2017; 1:4. [PMID: 29623957 PMCID: PMC5876694 DOI: 10.1186/s41236-017-0006-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 11/27/2017] [Indexed: 01/02/2023] Open
Abstract
Background Why does a tumor start where it does within an organ? Location is traditionally viewed as a random event, yet the statistics of the location of tumors argues against this being a random occurrence. There are numerous examples including that of breast cancer. More than half of invasive breast cancer tumors start in the upper outer quadrant of the breast near the armpit, even though it is estimated that only 35 to 40% of breast tissue is in this quadrant. This suggests that there is an unknown microenvironmental factor that significantly increases the risk of cancer in a spatial manner and that is not solely due to genes or toxins. We hypothesize that tumors are more prone to form in healthy tissue at microvascular ‘hot spots’ where there is a high local concentration of microvessels providing an increased blood flow that ensures an ample supply of oxygen, nutrients, and receptors for growth factors that promote the generation of new blood vessels. Results To show the plausibility of our hypothesis, we calculated the fractional probability that there is at least one microvascular hot spot in each region of the breast assuming a Poisson distribution of microvessels in two-dimensional cross sections of breast tissue. We modulated the microvessel density in various regions of the breast according to the total hemoglobin concentration measured by near infrared diffuse optical spectroscopy in different regions of the breast. Defining a hot spot to be a circle of radius 200 μm with at least 5 microvessels, and using a previously measured mean microvessel density of 1 microvessel/mm2, we find good agreement of the fractional probability of at least one hot spot in different regions of the breast with the observed invasive tumor occurrence. However, there is no reason to believe that the microvascular distribution obeys a Poisson distribution. Conclusions The spatial location of a tumor in an organ is not entirely random, indicating an unknown risk factor. Much work needs to be done to understand why a tumor occurs where it does. Electronic supplementary material The online version of this article (10.1186/s41236-017-0006-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Clare Yu
- 1Department of Physics and Astronomy, University of California, Irvine, CA 92697-4575 USA
| | | |
Collapse
|
10
|
Honeyman CS, Wilson P. Patient with giant upper limb melanoma presenting to a UK plastic surgery unit: differentials and experience of management. BMJ Case Rep 2016; 2016:bcr2015212253. [PMID: 26838295 PMCID: PMC4746506 DOI: 10.1136/bcr-2015-212253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/19/2016] [Indexed: 11/03/2022] Open
Abstract
A 57-year-old woman was referred to our regional sarcoma unit following a 2-year history of a progressively enlarging mass on her right forearm. At 14 × 7 × 12 cm, this mass turned out to be one of the largest upper limb cutaneous malignant melanomas ever described, and, to the best of our knowledge, the first documented in the UK. Remarkably, despite having a T4 malignant tumour with a Breslow thickness of 70 mm, this patient is still alive over 4 years later with no locoregional or distant metastatic spread. We present our experience in the management of this giant malignant melanoma of the upper limb and consider important differentials.
Collapse
Affiliation(s)
| | - Paul Wilson
- Department of Plastic Surgery, North Bristol NHS Trust, Bristol, UK
| |
Collapse
|
11
|
Hanin L, Bunimovich-Mendrazitsky S. Reconstruction of the natural history of metastatic cancer and assessment of the effects of surgery: Gompertzian growth of the primary tumor. Math Biosci 2013; 247:47-58. [PMID: 24211826 DOI: 10.1016/j.mbs.2013.10.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2013] [Revised: 10/05/2013] [Accepted: 10/25/2013] [Indexed: 11/29/2022]
Abstract
This work deals with retrospective reconstruction of the individual natural history of solid cancer and assessment of the effects of treatment on metastatic progression. This is achieved through a mathematical model of cancer progression accounting for the growth of the primary tumor, shedding of metastases, their dormancy and growth at secondary sites. To describe dynamics of the primary tumor, we used the Gompertz law, a parsimonious model of tumor growth accounting for its saturation. Parameters of the model were estimated from the age and volume of the primary tumor at surgery and volumes of detectable bone metastases collected from one breast cancer patient and one prostate cancer patient. This allowed us to estimate, for each patient, the ages at cancer onset and inception of all detected metastases, the expected metastasis latency time, parameters of the Gompertzian growth of the primary tumor, and the rates of growth of metastases before and after surgery. We found that for both patients: (1) onset of metastasis occurred when primary tumor was undetectable; (2) inception of all surveyed metastases except one occurred before surgery; and most importantly, (3) resection of the primary tumor led to a dramatic increase in the rate of growth of metastases. The model provides an excellent fit to the observed volumes of bone metastases in both patients. Our results agree well with those obtained previously based on exponential growth of the primary tumor, which serves as model validation. Our findings support the notion of metastatic dormancy and indirectly confirm the existence of stem-like cancer cells in breast and prostate tumors. We also explored the logistic law of primary tumor growth; however, it degenerated into the exponential law for both patients analyzed. The conclusions of this work are supported by a vast body of experimental, clinical and epidemiological knowledge accumulated over the last century.
Collapse
Affiliation(s)
- Leonid Hanin
- Department of Mathematics, Idaho State University, 921 S. 8th Avenue, Stop 8085, Pocatello, ID 83209-8085, USA.
| | | |
Collapse
|
12
|
Retsky M, Demicheli R, Hrushesky WJM, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem 2013; 20:4163-76. [PMID: 23992307 PMCID: PMC3831877 DOI: 10.2174/09298673113209990250] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2013] [Revised: 03/26/2013] [Accepted: 03/31/2013] [Indexed: 12/21/2022]
Abstract
To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to avascular micrometastases and then on to growing deposits. However in order to explain early relapses, we had to postulate that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth and then to detection. Most relapses in breast cancer are in the early category. Recent data from Forget et al. suggest an unexpected mechanism. They retrospectively studied results from 327 consecutive breast cancer patients comparing various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Relapse hazard updated Sept 2011 are presented. A common Non-Steroidal Anti-Inflammatory Drug (NSAID) analgesic used in surgery produced far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent.
Collapse
Affiliation(s)
- Michael Retsky
- Harvard School of Public Health, BLDG I, Rm 1311, 665 Huntington, Ave, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Hanin L. Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013; 734:261-82. [PMID: 23143983 DOI: 10.1007/978-1-4614-1445-2_12] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The hypothesis of early metastasis was debated for several decades. Dormant cancer cells and surgery-induced acceleration of metastatic growth were first observed in clinical studies and animal experiments conducted more than a century ago; later, these findings were confirmed in numerous modern studies.In this primarily methodological work, we discuss critically important, yet largely unobservable, aspects of the natural history of cancer, such as (1) early metastatic dissemination; (2) dormancy of secondary tumors; (3) treatment-related interruption of metastatic dormancy, induction of angiogenesis, and acceleration of the growth of vascular metastases; and (4) the existence of cancer stem cells. The hypothesis of early metastasis was debated for several decades. Dormant cancer cells and surgery-induced acceleration of metastatic growth were first observed in clinical studies and animal experiments conducted more than a century ago; later, these findings were confirmed in numerous modern studies.We focus on the unique role played by very general mathematical models of the individual natural history of cancer that are entirely mechanistic yet, somewhat paradoxically, essentially free of assumptions about specific nature of the underlying biological processes. These models make it possible to reconstruct in considerable detail the individual natural history of cancer and retrospectively assess the effects of treatment. Thus, the models can be used as a tool for generation and validation of biomedical hypotheses related to carcinogenesis, primary tumor growth, its metastatic dissemination, growth of metastases, and the effects of various treatment modalities. We discuss in detail one such general model and review the conclusions relevant to the aforementioned aspects of cancer progression that were drawn from fitting a parametric version of the model to data on the volumes of bone metastases in one breast cancer patient and 12 prostate cancer patients.
Collapse
Affiliation(s)
- Leonid Hanin
- Department of Mathematics, Idaho State University, Pocatello, ID 83209, USA.
| |
Collapse
|
14
|
Ching JA, Gould L. Giant scalp melanoma: a case report and review of the literature. EPLASTY 2012. [PMID: 23185647 PMCID: PMC3501267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Among malignant melanoma lesions, those occurring on the scalp and neck have a particularly poor prognosis. In this case report, we present the largest melanoma of the head and neck and one of the largest melanomas of any anatomic site reported in the literature to date. METHODS The biopsy revealed left scalp melanoma with a Breslow's thickness of at least 14 mm, and final needle aspiration of lymphadenopathy was consistent with malignant melanoma. Preoperative staging was T4aN3Mx. Wide local excision with 3-cm margins was performed, which included excision of the left ear en-bloc, along with a selective left neck dissection. Reconstruction was performed with a Bilayer Wound Matrix (Integra, 311 Enterprise Drive, Plainsboro, New Jersey) and eventual thin split-thickness skin graft. RESULTS Final pathology of the left scalp en-bloc excision was a 14.5 × 10.4 cm malignant melanoma, Breslow's thickness of 18 mm. Numerous lymph nodes were positive for melanoma as well. Final pathologic staging was determined to be T4b N3 M1, Stage IV. Later the patient underwent split-thickness skin graft placement on the left scalp acellular dermal matrix, which healed with complete graft take. DISCUSSION This case report demonstrates a unique presentation of a giant melanoma. With few other cases reported for comparison, it appears our patient's prognosis is poor, despite treatment according to current guidelines.
Collapse
Affiliation(s)
| | - Lisa Gould
- bJames A. Haley Veterans’ Hospital, University of South Florida, Tampa
| |
Collapse
|
15
|
Promising development from translational or perhaps anti-translational research in breast cancer. Clin Transl Med 2012; 1:17. [PMID: 23369485 PMCID: PMC3560986 DOI: 10.1186/2001-1326-1-17] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 08/24/2012] [Indexed: 11/23/2022] Open
Abstract
Background A great deal of the public’s money has been spent on cancer research but demonstrable benefits to patients have not been proportionate. We are a group of scientists and physicians who several decades ago were confronted with bimodal relapse patterns among early stage breast cancer patients who were treated by mastectomy. Since the bimodal pattern was not explainable with the then well-accepted continuous growth model, we proposed that metastatic disease was mostly inactive before surgery but was driven into growth somehow by surgery. Most relapses in breast cancer would fall into the surgery-induced growth category thus it was highly important to understand the ramifications of this process and how it may be curtailed. With this hypothesis, we have been able to explain a wide variety of clinical observations including why mammography is less effective for women age 40–49 than it is for women age 50–59, why adjuvant chemotherapy is most effective for premenopausal women with positive lymph nodes, and why there is a racial disparity in outcome. Methods We have been diligently looking for new clinical or laboratory information that could provide a connection or correlation between the bimodal relapse pattern and some clinical factor or interventional action and perhaps lead us towards methods to prevent surgery-initiated tumor activity. Results A recent development occurred when a retrospective study appeared in an anesthesiology journal that suggested the perioperative NSAID analgesic ketorolac seems to reduce early relapses following mastectomy. Collaborating with these anesthesiologists to understand this effect, we independently re-examined and updated their data and, in search of a mechanism, focused in on the transient systemic inflammation that follows surgery to remove a primary tumor. We have arrived at several possible explanations ranging from mechanical to biological that suggest the relapses avoided in the early years do not show up later. Conclusions We present the possibility that a nontoxic and low cost intervention could prevent early relapses. It may be that preventing systemic inflammation post surgery will prevent early relapses. This could be controlled by the surgical anesthesiologist’s choice of analgesic drugs. This development needs to be confirmed in a randomized controlled clinical trial and we have identified triple negative breast cancer as the ideal subset with which to test this. If successful, this would be relatively easy to implement in developing as well as developed countries and would be an important translational result.
Collapse
|
16
|
Effects of Surgery and Chemotherapy on Metastatic Progression of Prostate Cancer: Evidence from the Natural History of the Disease Reconstructed through Mathematical Modeling. Cancers (Basel) 2011; 3:3632-60. [PMID: 24212971 PMCID: PMC3759214 DOI: 10.3390/cancers3033632] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2011] [Revised: 09/09/2011] [Accepted: 09/15/2011] [Indexed: 12/17/2022] Open
Abstract
This article brings mathematical modeling to bear on the reconstruction of the natural history of prostate cancer and assessment of the effects of treatment on metastatic progression. We present a comprehensive, entirely mechanistic mathematical model of cancer progression accounting for primary tumor latency, shedding of metastases, their dormancy and growth at secondary sites. Parameters of the model were estimated from the following data collected from 12 prostate cancer patients: (1) age and volume of the primary tumor at presentation; and (2) volumes of detectable bone metastases surveyed at a later time. This allowed us to estimate, for each patient, the age at cancer onset and inception of the first metastasis, the expected metastasis latency time and the rates of growth of the primary tumor and metastases before and after the start of treatment. We found that for all patients: (1) inception of the first metastasis occurred when the primary tumor was undetectable; (2) inception of all or most of the surveyed metastases occurred before the start of treatment; (3) the rate of metastasis shedding is essentially constant in time regardless of the size of the primary tumor and so it is only marginally affected by treatment; and most importantly, (4) surgery, chemotherapy and possibly radiation bring about a dramatic increase (by dozens or hundred times for most patients) in the average rate of growth of metastases. Our analysis supports the notion of metastasis dormancy and the existence of prostate cancer stem cells. The model is applicable to all metastatic solid cancers, and our conclusions agree well with the results of a similar analysis based on a simpler model applied to a case of metastatic breast cancer.
Collapse
|
17
|
Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape? Cancers (Basel) 2011; 3:730-46. [PMID: 24212638 PMCID: PMC3756387 DOI: 10.3390/cancers3010730] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2010] [Revised: 01/28/2011] [Accepted: 02/11/2011] [Indexed: 01/05/2023] Open
Abstract
According to the concept of tumor dormancy, tumor cells may exist as single cells or microscopic clusters of cells that are clinically undetectable, but remain viable and have the potential for malignant outgrowth. At metastatic sites, escape from tumor dormancy under more favorable local microenvironmental conditions or through other, yet undefined stimuli, may account for distant recurrence after supposed "cure" following surgical treatment of the primary tumor. The vast majority of evidence to date in support of the concept of tumor dormancy originates from animal studies; however, extensive epidemiologic data from breast cancer strongly suggests that this process does occur in human disease. In this review, we aim to demonstrate that metastatic tumor dormancy does exist in cutaneous melanoma based on evidence from mouse models and clinical observations of late recurrence and occult transmission by organ transplantation. Experimental data underscores the critical role of impaired angiogenesis and immune regulation as major mechanisms for maintenance of tumor dormancy. Finally, we examine evidence for the role of surgery in promoting escape from tumor dormancy at metastatic sites in cutaneous melanoma.
Collapse
|
18
|
Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models. Cancers (Basel) 2011; 3:340-67. [PMID: 24212619 PMCID: PMC3756365 DOI: 10.3390/cancers3010340] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Revised: 01/06/2011] [Accepted: 01/11/2011] [Indexed: 12/15/2022] Open
Abstract
We discuss philosophical, methodological, and biomedical grounds for the traditional paradigm of cancer and some of its critical flaws. We also review some potentially fruitful approaches to understanding cancer and its treatment. This includes the new paradigm of cancer that was developed over the last 15 years by Michael Retsky, Michael Baum, Romano Demicheli, Isaac Gukas, William Hrushesky and their colleagues on the basis of earlier pioneering work of Bernard Fisher and Judah Folkman. Next, we highlight the unique and pivotal role of mathematical modeling in testing biomedical hypotheses about the natural history of cancer and the effects of its treatment, elaborate on model selection criteria, and mention some methodological pitfalls. Finally, we describe a specific mathematical model of cancer progression that supports all the main postulates of the new paradigm of cancer when applied to the natural history of a particular breast cancer patient and fit to the observables.
Collapse
|
19
|
Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I. Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth? Cancers (Basel) 2010; 2:305-37. [PMID: 24281072 PMCID: PMC3835080 DOI: 10.3390/cancers2020305] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2010] [Revised: 03/25/2010] [Accepted: 03/26/2010] [Indexed: 12/16/2022] Open
Abstract
We review our work over the past 14 years that began when we were first confronted with bimodal relapse patterns in two breast cancer databases from different countries. These data were unexplainable with the accepted continuous tumor growth paradigm. To explain these data, we proposed that metastatic breast cancer growth commonly includes periods of temporary dormancy at both the single cell phase and the avascular micrometastasis phase. We also suggested that surgery to remove the primary tumor often terminates dormancy resulting in accelerated relapses. These iatrogenic events are apparently very common in that over half of all metastatic relapses progress in that manner. Assuming this is true, there should be ample and clear evidence in clinical data. We review here the breast cancer paradigm from a variety of historical, clinical, and scientific perspectives and consider how dormancy and surgery-driven escape from dormancy would be observed and what this would mean. Dormancy can be identified in these diverse data but most conspicuous is the sudden synchronized escape from dormancy following primary surgery. On the basis of our findings, we suggest a new paradigm for early stage breast cancer. We also suggest a new treatment that is meant to stabilize and preserve dormancy rather than attempt to kill all cancer cells as is the present strategy.
Collapse
Affiliation(s)
- Michael Retsky
- Harvard School of Public Health, BLDG I, Rm 1311, 665 Huntington, Ave., Boston, MA 02115, USA
| | - Romano Demicheli
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano, Italy; E-Mail:
| | - William Hrushesky
- University of South Carolina, School of Medicine, Columbia, SC, USA; E-Mail:
| | - Michael Baum
- Royal Free and UCL Medical School, Centre for Clinical Science and Technology, Clerkenwell Building, Archway Campus, Highgate Hill, London, N19 5LW, UK; E-Mail:
| | - Isaac Gukas
- Breast Unit, Department of General Surgery, James Paget University Hospital, Gorleston, Great Yarmouth, UK; E-Mail:
| |
Collapse
|